Keyphrases
Pediatric
64%
Japan
64%
Hematopoietic Stem Cell Transplantation
50%
Acute Lymphoblastic Leukemia
49%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
43%
Pediatric Patients
37%
BCP-ALL
37%
Prognostic Factors
25%
Unrelated Cord Blood Transplantation
24%
UDP-glucuronosyltransferase
21%
Revised International Prognostic Scoring System
21%
Histiocytic Sarcoma
21%
MAP2K1
21%
Abnormality Classification
21%
MYC Rearrangement
21%
Chromosome 8q24
21%
NUDT15
21%
Asian Families
21%
Hypodiploidy
21%
Killer Cell Immunoglobulin-like Receptor
21%
Hemoglobin
21%
Second Malignancy
21%
Disease-free Survival
21%
Allogeneic Transplantation
21%
Pediatric Cancer
21%
Aprepitant
21%
Philadelphia Chromosome-negative
21%
Ligand-receptor Binding
21%
Parents of children with Cancer
21%
Prognostic Value
21%
Pathogenic Variants
21%
Cytogenetic Abnormalities
21%
8q24
21%
Posttraumatic Growth
21%
Polypeptide
21%
Nationwide Survey
21%
Leukemia
21%
Fosaprepitant
21%
Deletion Polymorphism
21%
MEK Inhibitor (MEKi)
21%
Childhood Acute Lymphoblastic Leukemia
21%
Kinase Fusion
21%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
21%
High Incidence
21%
Maintenance Chemotherapy
21%
Outcome Prediction
21%
Second Malignant Neoplasm
21%
Trametinib
21%
Myelodysplastic Syndrome
21%
Pediatric Myelodysplastic Syndrome
21%
Medicine and Dentistry
Pediatrics
100%
Acute Lymphoblastic Leukemia
86%
Malignant Neoplasm
54%
Precursor
43%
B Cell
43%
Leukemia in Children
43%
Acute Myeloid Leukemia
43%
Pediatrics Patient
37%
Acute Leukemia
30%
Leukemia
28%
Chemotherapy
27%
Diseases
23%
Glucuronosyltransferase
21%
International Prognostic Scoring System
21%
Phosphotransferase
21%
MEK Inhibitor
21%
Histiocytic Sarcoma
21%
Trametinib
21%
Valine
21%
Globin
21%
Posttraumatic Growth
21%
Second Cancer
21%
Pediatric Cancer
21%
Methionine
21%
Hemolytic Anemia
21%
Maintenance Chemotherapy
21%
Myelodysplastic Syndrome
21%
Genetic Screening
21%
Prognosis
21%
Polypeptide
21%
Disease Free Survival
21%
Hematopoietic Stem Cell Transplantation
21%
Pediatric Myelodysplastic Syndrome
21%
Medical Device
21%
Overall Survival
20%
Cancer
16%
Maintenance Therapy
16%
Mercaptopurine
14%
Janus Kinase
14%
Onset Age
14%
Tyrosine-Kinase Inhibitor
14%
Disease
13%
Neoplasm
12%
Genetic Analysis
12%
Burkitt's Lymphoma
10%
Hazard Ratio
10%
Recurrence Risk
9%
Pediatric Acute Myeloid Leukemia
9%
Stem Cell
8%
Survival Rate
7%
Biochemistry, Genetics and Molecular Biology
Hematopoietic Stem Cell Transplantation
43%
Precursor
43%
B Cell
43%
Cytogenetics
29%
Prevalence
28%
Germline
25%
Germ Cell
25%
Overall Survival
25%
Glucuronosyltransferase
21%
Disease Free Survival
21%
Platelet Derived Growth Factor Receptor Beta
21%
Kinase
21%
Phosphotransferase
21%
Mercaptopurine
21%
Methionine
21%
Globin
21%
Genetics
19%
Survival Rate
17%
Janus Kinase
14%
Tyrosine Kinase Inhibitor
14%
CRLF2
14%
Sample Size
10%
TCF3
10%
RUNX1
10%
Clinical Study
10%
Ploidy
10%
ETV6
10%
PBX1
10%
Prednisolone
10%
Genetic Variation
8%
Genetic Divergence
8%
Exome Sequencing
8%
Last Year Needle
7%
Event Free Survival
7%
Tyrosine Kinase Receptor
7%
Cytokine Receptor
7%
IKZF1
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Leukocyte Count
7%
Gene Expression Profiling
7%
Intron
5%
Microarrays
5%
Karyotype
5%
Genomics
5%
PMS2
5%
PTCH1
5%
Genetic Background
5%
Genetic Determinism
5%